Gene-expression of metastasized versus non-metastasized primary head and neck squamous cell carcinomas: A pathway-based analysis

Erik F Hensen*1,2, Maria J De Herdt2, Jelle J Goeman3, Jan Oosting2, Vincent THBM Smit2, Cees J Cornelisse2 and Robert J Baatenburg de Jong4

Address: 1Department of Otolaryngology and Head and Neck Surgery, Leiden University Medical Centre, Leiden, The Netherlands, 2Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands, 3Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands and 4Department of Otolaryngology and Head and Neck Surgery, Erasmus Medical Centre Rotterdam, The Netherlands

Email: Erik F Hensen* - e.f.hensen@lumc.nl; Maria J De Herdt - m.deherdt@erasmusmc.nl; Jelle J Goeman - j.j.goeman@lumc.nl; Jan Oosting - j.oosting@lumc.nl; Vincent THBM Smit - v.t.h.b.m.smit@lumc.nl; Cees J Cornelisse - c.j.cornelisse@lumc.nl; Robert J Baatenburg de Jong - r.j.baatenburgdejong@erasmusmc.nl

* Corresponding author

Abstract

Background: Regional lymph node metastasis is an important prognostic factor in head and neck squamous cell carcinoma (HNSCC) and plays a decisive role in the choice of treatment. Here, we present an independent gene expression validation study of metastasized versus non-metastasized HNSCC.

Methods: We used a dataset recently published by Roepman et al. as reference dataset and an independent gene expression dataset of 11 metastasized and 11 non-metastasized HNSCC tumors as validation dataset. Reference and validation studies were performed on different microarray platforms with different probe sets and probe content. In addition to a supervised gene-based analysis, a supervised pathway-based analysis was performed, evaluating differences in gene expression for predefined tumorigenesis- and metastasis related gene sets.

Results: The gene-based analysis showed 26 significant differentially expressed genes in the reference dataset, 21 of which were present on the microarray platform used in the validation study. 7 of these genes appeared to be significantly expressed in the validation dataset, but failed to pass the correction for multiple testing. The pathway-based analysis revealed 23 significant differentially expressed gene sets, 7 of which were statistically validated. These gene sets are involved in extracellular matrix remodeling (MMPs, MMP regulating pathways and the uPA system), hypoxia and angiogenesis (HIF1α regulated angiogenic factors and HIF1α regulated invasion).

Conclusion: Pathways that are differentially expressed between metastasized and non-metastasized HNSCC are involved in the processes of extracellular matrix remodeling, hypoxia and angiogenesis. A supervised pathway-based analysis enhances the understanding of the biological context of the results, the comparability of results across different microarray studies, and reduces multiple testing problems by focusing on a limited number of pathways of interest instead of analyzing the large number of probes available on the microarray.

Published: 10 June 2008

BMC Cancer 2008, 8:168 doi:10.1186/1471-2407-8-168

Received: 18 October 2007 Accepted: 10 June 2008

This article is available from: http://www.biomedcentral.com/1471-2407/8/168

© 2008 Hensen et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Head and neck squamous cell carcinoma is a relatively common malignancy, associated with severe disease- and treatment-related morbidity. One of the most predictive factors of poor clinical outcome is the presence of regional lymph node metastasis, and nodal status of the neck plays a decisive role in the choice of treatment [1, 2]. The complex process of metastasis in HNSCC is still incompletely understood at a molecular level; however, multiple marker studies have been performed in order to identify markers that predict the presence of metastasis. Recently, high-throughput gene expression studies have been able to identify a metastatic gene expression signature in primary HNSCC tumors, and Roepman et al. were able to predict the presence of lymph node metastasis based on gene expression of the primary tumor [3]. Analyses in this study were performed in a ‘data-driven’ way, by means of computational statistics without prior implementation of existing knowledge about functionally related genes and pathways. This technique is very useful in the search for new biomarkers, new subgroups, and differences in their gene expression profiles. Although the authors were able to identify a number of genes that are known to be involved in metastatic disease within this gene set, the interpretation of statistical differences in a meaningful molecular biological context is not self-evident. It has been demonstrated that classification gene sets are profoundly influenced by the microarray methodology, such as the microarray technique, microarray platform, and preprocessing methods [4-8]. Furthermore, it has been shown that classifying gene sets are highly dependent on the chosen analysis strategy [9, 10]. This is illustrated by the fact that the authors were able to generate several different classifying gene sets that were all able to predict nodal metastasis with reasonable accuracy [10]. The dependence of classifying gene sets on statistical methods, as well as technical methods such as choice of microarray platform, hampers comparability of results from different microarray studies and raises questions about the biological relevance of the classifying genes. It is therefore necessary that differences in gene expression are validated in an independent dataset. Here, we present an independent gene expression validation study of metastasized versus non-metastasized HNSCC. Differences in gene expression between metastasized and non-metastasized HNSCC were determined in the publicly available dataset generated by Roepman et al., and subsequently validated in an independent gene expression dataset of 11 metastasized and 11 non-metastasized HNSCC tumors of three anatomical localizations (the oral cavity, the oropharynx and the larynx). In addition to the validation of individual differentially expressed genes, we performed a supervised, pathway-based analysis. Gene expression was evaluated within predefined subgroups of genes with a known biological context, i.e. genes within a metastasis related pathway. First, pathways and functional gene clusters that are involved in the process of metastasis in carcinoma were defined using pathways described in literature and the publicly available Kyoto Encyclopedia of Genes and Genomes (KEGG) and Biocarta pathway databases, with a focus on pathways involved in survival, proliferation, apoptosis, cell adhesion, extra cellular matrix signaling and remodeling, hypoxia and angiogenesis [11-13]. Using this supervised analysis strategy, we found considerable concordance between the datasets for pathways involved in survival, proliferation, apoptosis, cell adhesion, extra cellular matrix signaling and remodeling, hypoxia and angiogenesis. Gene sets that were validated by the independent validation dataset were matrix metalloproteinases (MMPs) and pathways involved in MMP regulation, the uPA system and pathways involved in uPA regulation, and HIF1α regulated invasion and angiogenesis. This approach to microarray analysis generates an outcome with readily interpretable biological meaning. Furthermore, by concentrating on groups of genes with a known biological relation rather than individual genes, comparability of microarray studies performed on different microarray platforms is improved [14].

Methods

Reference dataset

The publicly available HNSCC gene expression dataset published by Roepman and co-workers was used as the reference dataset [3, 15]. All 104 samples (49 non-metastasized and 55 metastasized primary head and neck carcinoma’s) analyzed in this study were included the reference dataset (Table 1). For sample selection, cRNA preparation, microarray hybridization and normalization methods in this study see elsewhere [3].

Validation dataset

Sample selection

An independent validation dataset was constructed using fresh frozen tumor tissue of 24 patients with an HNSCC originating from the oral cavity, the oropharynx, or the larynx. Primary tumors were removed between 1990 and 2000. Specimens were selected from the frozen tissue bank of the Leiden University Medical Centre (LUMC), the Netherlands. Neck dissection specimens of all cases were available for histological evaluation of lymph nodes. Based on histology obtained from surgical specimens as well as clinical and radiological data collected during a follow-up period of four years or more, the group was divided into a non-metastasized and a metastasized subgroup. The non-metastasized group consisted of 12 tumors (4 from the oral cavity, 4 oropharyngeal and 4 laryngeal HNSCC) from patients without indication of metastasis at the time of surgery, nor during the follow-up period. The metastasized group also consisted of 12 tumors (4 from the oral cavity, 4 oropharyngeal and 4
Total RNA was precipitated with glycogen and isopropanol, washed with ethanol and purified using the RNeasy Mini Kit (Qiagen, Valencia, CA). Total RNA yield and purity were measured using spectrophotometric analysis and in addition RNA quality was checked on a 1% agarose gel. Double-stranded cDNA synthesis was performed using the Superscript Choice system (Life Technologies, Rockville, MD): incorporating the T7 RNA polymerase promoter in the first round. The resulting ds cDNA was purified using the QIAquick PCR Purification Kit (Qiagen, Valencia, CA), and applied as a template for in vitro transcription using the RNA Transcript Labeling Kit (Enzo Diagnostics, Inc., Farmingdale, NY), incorporating biotinylated ribonucleotides required for the staining procedures after hybridization. The resulting cRNA was purified as described above and cRNA quantity and quality were measured using spectrophotometric analysis and the 2100 Bioanalyzer (Agilent, Palo Alto, CA). 15 μg fragmented, biotinylated cRNA was hybridized to the Affymetrix HG-Focus Target arrays at 45°C for 16 h. After hybridization the arrays were washed, stained and scanned, as described in the Affymetrix users’ manual.

### Statistical analysis

**Normalization and expression analysis**

In the validation study, acquisition and quantification of array images was performed using the MAS software package (Affymetrix). All arrays were normalized with gcma normalization and custom probe definitions based on EntrezGene identifiers using the R statistical software package available on Bioconductor [17-20].

**Supervised analysis**

The R package 'Linear Models for Microarray Data' (LIMMA) was used for the assessment of differential expression between N0 and N+ HNSCC subgroups in the reference dataset [21]. Multiple testing correction was performed using False Discovery Rate (FDR) analysis [22]. The reference dataset was used as the hypothesis generating dataset, and genes with a FDR adjusted p-value < 0.1 were included in the gene set that was subsequently validated using the independent validation dataset. Genes were considered to be validated by the validation dataset if an FDR adjusted p-value < 0.05 was reached.

In the study by Roepman et al. it was reported that longer sample storage time had an adverse effect on the predictive value of classifying genes, and that the classifying gene set based on samples stored after 1998 had a higher accuracy [3]. In order to evaluate whether storage time had an effect on the gene-based analysis in this study, we performed an additional LIMMA analysis on samples stored after 1998 in the reference dataset and subsequently validated the outcome using samples stored after 1998 in the validation dataset.

### Table 1: Characteristics of tumors included in the reference and validation dataset

| Characteristic                        | Reference set | Validation set |
|---------------------------------------|---------------|----------------|
| Sex (n – %)                           |               |                |
| Male                                  | 60 (58%)      | 14 (64%)       |
| Female                                | 44 (42%)      | 8 (36%)        |
| Location of primary tumor (n – %)     |               |                |
| oral cavity                           | 87 (84%)      | 7 (32%)        |
| oropharynx                            | 17 (16%)      | 7 (32%)        |
| larynx                                | 0 (0%)        | 8 (36%)        |
| Primary tumor size (n – %)            |               |                |
| Maximal diameter (cm.)                |               |                |
| < 2.5                                 | 33 (32%)      | 0 (0%)         |
| 2.5 – 5.0                             | 49 (47%)      | 13 (59%)       |
| > 5.0                                 | 22 (21%)      | 9 (41%)        |
| Nodal metastasis (n – %)              |               |                |
| no (N0)                               | 49 (47%)      | 11 (50%)       |
| yes (N+)                              | 55 (53%)      | 11 (50%)       |

Laryngeal HNSCC) from patients with lymph node metastasis at the time of surgery or during the follow-up period (Table 1). In all cases fresh frozen tissue of the primary tumor containing a tumor percentage of 50% or more, paraffin material, an unequivocal pathological classification of the resection material and clinical data were available. Patients who had undergone radiotherapy before surgical excision of the tumor or had a previous malignancy in the same region were excluded. All specimens were handled according to the ethical guidelines, as described in the Code for Proper Secondary Use of Human Tissue in the Netherlands of the Dutch Federation of Medical Scientific Societies (FEDERA). The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (GEO), and are accessible through GEO Series accession number GSE9349 [16].

**High-density oligonucleotide arrays**

Data from the reference dataset were obtained with the Human Array-Ready Oligo set, version 2.0 (Qiagen) printed on Corning UltraGAPS slides, containing over 21,000 genes. These data were compared to the data from the validation set, obtained with Affymetrix HG-Focus Target arrays (Affymetrix, Inc., Santa Clara, CA) as microarray platform, containing over 190,000 unique oligonucleotides, representing more than 8,500 of the best characterized human genes.

**Total RNA isolation, probe preparation and hybridization to arrays**

Total RNA isolation, probe preparation and hybridization to arrays were performed according to the Affymetrix protocols. In short, total RNA was extracted from fresh frozen tumor sections using Trizol (Invitrogen, San Diego, CA).
**Pathway selection and analysis**

In order to acquire metastatic potential, a primary tumor cell must complete a series of sequential steps, including progressive growth at the primary tumor site, vascularisation of the primary tumor, invasion of the surrounding stroma, detachment from other tumor cells, embolization of tumor cells in blood vessels or lymph vessels, survival within these vessels, extravasation and proliferation at the metastatic site [23]. Each of these steps is regulated by transient or permanent changes in DNA, RNA or proteins. We have defined pathways and gene sets involved in each of these steps using the publicly available pathway databases KEGG and Biocarta, and by researching literature on metastasis in (head and neck) carcinoma [11-13]. We categorized these pathways in the following subgroups: survival, proliferation, differentiation, apoptosis, cell adhesion, extra cellular matrix signaling and remodeling, hypoxia and angiogenesis. In all, 241 gene sets were thus created. In order to determine if gene expression was significantly different between metastasized and non-metastasized HNSCC in the reference dataset, we performed the global test designed by J.J. Goeman (available as the R package ‘globaltest’ at Bioconductor) on each predefined pathway [19,20,24]. The reference dataset was used as the hypothesis generating dataset, and all pathways with a FDR adjusted p-value < 0.1 were accepted for validation in the independent validation dataset. Pathways were considered to be validated by the validation dataset if an FDR adjusted p-value < 0.05 was reached.

**Results**

**Unsupervised analysis of the validation dataset**

2 out of 24 hybridizations were of insufficient quality, leaving 22 samples in the analysis (11 metastasized and 11 non-metastasized samples) (Table 1). No differences were observed in total RNA and cRNA yield or quality between samples with different storage time. After normalization of the validation dataset, there was a great similarity in gene-expression profiles irrespective of their N-stage or location in the oral cavity, oropharynx, or larynx. Complete linkage two-way hierarchical clustering revealed no well-defined grouping of samples according to their N-stage or location. No grouping was found according to sample storage time. We also performed this clustering analysis separately for each subgroup (according to localization or N-stage), but found no stable clusters (data not shown).

**Supervised gene-based analysis**

LIMMA analysis revealed 31 significant differentially expressed oligonucleotide transcripts within the reference dataset, when corrected for multiple testing (FDR adjusted p-value < 0.1). Twenty-six of these 31 transcripts represented well-defined genes. Twenty-one of these 26 well-defined genes were also represented on the HG U95 Av2 chip used in creating the validation dataset. Seven of these 21 genes appeared to be significantly expressed in the validation dataset (raw p value < 0.05). However, all failed to pass the correction for multiple testing (FDR adjusted p-value < 0.05). These genes are lethal giant larvae protein 2 of Drosophila (LGL2), fibroblast activation protein alpha (FAP), urokinase plasminogen activator (PLAU), laminin beta 1 (LAMB1), musculin (MSC), and collagen type V alpha 1 and 3 subunits (COL5A1 and COL5A3) (Table 2). Next, in analogy with the study by Roepman et al., we performed LIMMA analysis on the samples stored after 1998 only (66 samples in the reference dataset and 8 in the validation dataset) [3]. This revealed 352 differentially expressed well-defined genes in the reference dataset when corrected for multiple testing. However, none of these genes could be validated (FDR adjusted p-value < 0.05) in the validation dataset (data not shown).

**Supervised pathway-based analysis**

Analysis of the selected pathways related to survival, proliferation, apoptosis, cell adhesion, extra cellular matrix signaling and remodeling, hypoxia and angiogenesis, revealed significant differential expression for 23 gene sets in the reference dataset. These gene sets mainly encode extracellular matrix components (i.e. collagens), and pathways involved in extracellular matrix remodeling (MMPs, the uPA system, uPA regulating pathways, and HIF1α regulated invasion), hypoxia (upregulation of HIF1α target genes) and hypoxia induced angiogenesis (HIF1α regulated angiogenic factors). Of these 23 gene sets, 7 gene sets were validated by analysis of the independent expression dataset when corrected for multiple testing (Table 3 and 4). These gene sets with significant differential expression between N0 and N+ tumors in both datasets are involved in extracellular matrix remodeling (MMPs, MMP regulating pathways and the uPA system), hypoxia and angiogenesis (HIF1α regulated angiogenic factors and HIF1α regulated invasion) (Table 4 and 5, Figure 1). No significant differential expression between metastasized and non-metastasized HNSCC was shown for 215 gene sets in both datasets, including almost all survival, proliferation and apoptosis related gene sets (Table 3).

**Discussion**

It has been demonstrated that the outcome of microarray studies is profoundly influenced by the chosen analysis strategy and highly dependent on technical aspects such as sample preparation methods and choice of microarray platform [4-10]. This raises questions about the biological validity of the outcome of individual studies, and the validation of microarray studies is therefore essential. Here we present the results of an independent validation analysis of differences in gene expression between metastasized and non-metastasized HNSCC. The reference study
and validation study were performed in different centers by different investigators, using different microarray platforms with different probe content. In this study, we concentrated on the validation and biological interpretation of the differences in gene expression between N0 and N+ HNSCC subgroups, and did not attempt to validate classifying gene sets that predict N-status in the reference study or other HNSCC microarray studies, because the data-driven way in which these classifying gene sets are created makes them too dependent on the microarray platform, the microarray technique, the preprocessing methods and the laboratory used to create them [4-8]. Furthermore, gaining insight into the process of metastasis on the basis of these classifying gene sets is troublesome: although some probes within the classifier encode a gene with a known role in tumorigenesis or metastasis, many others have unrelated or unknown functions [3]. The fact that multiple classifying gene sets can be constructed on basis of the reference study data casts further doubts on their biological validity [10]. In this study, a gene-based analy-

Table 2: Differentially expressed genes between N0 and N+ HNSCC as validated by the independent expression dataset

| Gene  | GenBank ID | Function                  | P-Value | P-Value (FDR adjusted) |
|-------|------------|---------------------------|---------|------------------------|
| LLGL2 | NM_001031803 | cell division and migration | 0.011   | 0.116                  |
| FAP   | NM_004460  | ecm remodelling            | 0.013   | 0.116                  |
| PLAU  | NM_002658  | ecm remodelling            | 0.017   | 0.116                  |
| LAMB1 | NM_002291  | basement membrane component | 0.022  | 0.116                  |
| MSC   | NM_005098  | transcription factor       | 0.030   | 0.126                  |
| COLSA1| NM_000093  | ecm component              | 0.039   | 0.134                  |
| COLSA3| NM_015719  | ecm component              | 0.045   | 0.134                  |
| COL4A1| NM_001845  | ecm component              | 0.077   | 0.201                  |
| LAMA4 | NM_002290  | basement membrane component | 0.103  | 0.240                  |
| CYB5R3| NM_000398  | Metabolism                 | 0.237   | 0.488                  |
| CSTA  | NM_005213  | cell envelope              | 0.255   | 0.488                  |
| PL    | NM_002705  | cell envelope              | 0.283   | 0.496                  |
| NTHL1 | NM_002528  | DNA damage repair          | 0.454   | 0.682                  |
| TNFAIP3| NM_006290  | inhibit TNF-mediated apoptosis. | 0.477  | 0.682                  |
| TTYH1 | NM_020659  | chloride anion channel     | 0.487   | 0.682                  |
| PALM2-AKAP2| NM_147150 | Unknown                    | 0.617   | 0.809                  |
| SCRG1 | NM_007281  | response to prion-associated infection | 0.727  | 0.866                  |
| ADAM12| NM_021641  | ecm remodelling            | 0.742   | 0.866                  |
| FADS1 | NM_013402  | Metabolism                 | 0.869   | 0.888                  |
| SOX4  | NM_003107  | apoptosis and survival     | 0.876   | 0.888                  |
| IVL   | NM_005547  | cell envelope              | 0.888   | 0.888                  |
| FNI   | NM_212482  | cell adhesion and migration | -      | -                      |
| PELO  | NM_181501  | cell cycle control         | -       | -                      |
| FBXL19| NM_019085  | F-box protein              | -       | -                      |
| DMKN  | NM_033317  | Unknown                    | -       | -                      |
| EPKK1 | NM_031308  | cell adhesion              | -       | -                      |

ecm = extra cellular matrix. P-value = raw p-value of the LIMMA analysis. P-value (FDR adjusted) = p-value of the LIMMA analysis, corrected for multiple testing. P-values for genes that were not represented on the Affymetrix HG U95Av2 microarray used for the validation dataset are missing. Differentially expressed genes are considered to be validated by the validation dataset if the FDR adjusted p-value is smaller than 0.05. Although the first 7 genes (LLGL2, FAP, PLAU, LAMB1, MSC, COLSA1 and COLSA3) score a raw p-value smaller than 0.05, none of them pass the correction for multiple testing.

Table 3: Number of pathways with significant differential expression between N0 and N+ HNSCC in the reference and validation datasets

| Pathways significant in reference dataset | Pathways significant in validation dataset | Pathways not significant in validation dataset |
|-------------------------------------------|--------------------------------------------|-----------------------------------------------|
| Pathways significant in validation dataset | Pathways not significant in validation dataset | 7                                            |
| Pathways not significant in reference dataset | 3                                    | 16                                           |
| Pathways not significant in reference dataset | 10                                    | 215                                          |

In all, 241 different tumorigenesis and metastasis related pathways were tested. 23 significant differentially expressed pathways were found in the reference dataset, and 10 in the validation dataset, 7 of which overlapped. 215 pathways showed no significant differential gene expression in both datasets.
Heatmap of pathways with validated differential gene expression between non-metastasized and metastasized primary HNSCC. Each row in the figure denotes a gene and each column denotes a sample. Panel on the left: validated differentially expressed pathways in the reference study. Panel on the right: validated differentially expressed pathways in the validation study. Relative gene-expression is shown for each gene in the pathway, and for each sample in the N0 and N1 HNSCC subgroups, red indicating overexpression and green indicating underexpression. White brackets indicate genes not represented on the respective microarray platforms.
### Table 4: Validated pathways with significant differential expression between N0 and N+ HNSCC

| Pathways                        | Genes in pathway | Probes in reference dataset (n) | Probes in validation dataset (n) | p-value | p-value (FDR adjusted) |
|---------------------------------|------------------|---------------------------------|----------------------------------|---------|------------------------|
| MAPK 1/3 regulated MMPs         | 16               | 17                              | 14                               | 0.003   | 0.028                  |
| JNK/MAPK regulated MMPs        | 25               | 28                              | 19                               | 0.003   | 0.028                  |
| MAPK 1/3 regulated invasion     | 35               | 38                              | 30                               | 0.004   | 0.028                  |
| MMPs                            | 9                | 8                               | 8                                | 0.005   | 0.028                  |
| HIF1α regulated invasion       | 14               | 11                              | 11                               | 0.011   | 0.048                  |
| HIF1α regulated angiogenesis    | 26               | 21                              | 19                               | 0.013   | 0.048                  |
| uPA system                      | 3                | 3                               | 2                                | 0.015   | 0.048                  |

Genes in pathway = number of genes theoretically involved in the pathway. Probes in reference dataset = number of probes representing pathway genes in the reference dataset. Probes in validation dataset = number of probes representing pathway genes in the validation dataset. P-value = raw p-value of the global test. P-value (FDR adjusted) = p-value of the global test, corrected for multiple testing using the false discovery rate. Differentially expressed pathways are considered to be validated by the validation dataset if the FDR adjusted p-value is smaller than 0.05.

### Table 5: Genes included in the pathways and functional gene sets that are differentially expressed between metastasized and non-metastasized HNSCC

| uPA system | HIF1α regulated angiogenesis | HIF1α regulated invasion | MMPs in HNSCC | MAPK 1/3 regulated invasion | JNK/MAPK regulated MMPs | MAPK 1/3 regulated MMPs |
|------------|------------------------------|--------------------------|---------------|------------------------------|-------------------------|--------------------------|
| PLAUR      | HGF                          | HIF1α                     | MMP1          | SHC1                         | HRAS                    | SHC1                     |
| PLG        | FGF2                         | MMP2                     | MMP2          | GRB2                         | RAC1                    | GRB2                     |
|            | PDGFB                        | MMP13                     | MMP3          | SOS1                         | PAK2                    | SOS1                     |
|            | IL8                          | PLAU                     | MMP6          | HRAS                         | PAK2                    | HRAS                     |
|            | PGF                          | P4HA1                     | MMP7          | RAF1                         | MAP3K4                  | RAF1                     |
|            | ANGPT2                       | CXCL12                    | MMP9          | MAP2K1                       | MAP3K1                  | MAP2K1                   |
|            | TEK                          | MMP14                     | MMP10         | MAP2K2                       | MAP3K12                 | MAP2K2                   |
|            | MMP2                         | COLSA1                    | MMP11         | MAPK3                        | MAP2K7                  | MAPK3                    |
|            | MMP13                        | CTGF                      | MMP14         | MAPK1                        | MAP2K4                  | MAPK1                    |
|            | PLAU                         | ITG2                      | RPS6K5        | MAPK8                        | FOS                     |                          |
|            | CCL2                         | SERPINE 1                 | RPS6K1        | MAPK9                        | MMP1                    |                          |
|            | CXCL12                       | CXCR 4                    | MKNN1         | MAPK10                       | MMP3                    |                          |
|            | VEGFCA                       | MET                       | MKNN2         | JUN                          | MMP7                    |                          |
|            | FLT 1                        | ETS 1                     | MYC           | AT1F2                        | MMP9                    |                          |
|            | IGFBP1                       | STAT3                     | ELK1          | SP1                          | MMP10                   |                          |
|            | SERPINE 1                    | TERT                      | ELK4          | CDC42                        |                          |                          |
|            | P4HA1                        | SRF                       | ELK4          | CD44                         |                          |                          |
|            | CXC4R 4                      | ATV4                      | FOS           | MMP1                         |                          |                          |
|            | COLSA1                       | RAS2A                     | RAS7          | MMP7                         |                          |                          |
|            | CTGF                         | NF1                       | RASA1         | MMP10                        |                          |                          |
|            | MMP14                        | RASGRF1                   | RASGRF2       | MMP13                        |                          |                          |
|            | HIF1α                        | RAPGEF2                   | PRKCA         | CD44                         |                          |                          |
|            | ENG                          | CD44                      | MMP1          |                          |                          |                          |
|            | EDN 1                        | MMP3                      | MMP7          |                          |                          |                          |
|            | LRP 1                        | MMP9                      | MMP10         |                          |                          |                          |
|            | CITED 2                      | MMP13                     |                |                          |                          |                          |
sis revealed 7 genes that appeared to be significantly expressed in the validation dataset (raw p value < 0.05) (Table 2). All of these 7 genes are known to be involved in processes of tumorigenesis or metastasis. LLGL2 belongs to a group of genes that act as tumor suppressor genes. Loss of function is associated with disruption of cell polarity and tissue architecture, uncontrolled proliferation and growth of neoplastic lesions [25]. FAP is a cell-surface protease expressed in reactive stromal fibroblasts of epithelial cancers, and is associated with invasion and metastasis in gastric, colorectal and cervical carcinoma [26-28]. PLAU encodes a serine protease involved in degradation of the extracellular matrix. Its plays a well-known role in invasion and metastasis of carcinoma, and is a prognostic factor for metastasis and outcome [29,30]. LAMB1 encodes the β1 subunit of members from the laminin family, extracellular matrix glycoproteins that are the major non-collagenous constituent of basement membranes. Laminins containing the β1 subunit (i.e. laminin 8 and 10) have been implicated in the metastasis related processes of angiogenesis, invasion, and migration [31,32]. The protein encoded by MSC is a transcriptional repressor that attenuates E2A-mediated gene activation. MSC overexpression is associated with loss of differentiation in multiple tissues and is associated with B-cell lymphoma, but no association with epithelial cancer has been described to date [33,34]. COL5A1 and COL5A3 encode alpha chains of collagen type 5. Upregulation is associated with metastatic potential in carcinoma [3,35]. However, when corrected for multiple testing, none of these genes could be statistically validated.

Roepman et al. have reported an adverse effect of long-term storage of tissue samples on its predictive accuracy. No explanation was found for this phenomenon, but it did not seem to be attributable to differences in total RNA and cRNA yield or quality [3]. We have evaluated the effect of storage time on the gene-based validation analysis in this study. Our LIMMA analysis of the most recent tumor samples within the reference dataset identified more differentially expressed genes, an observation that seems to correlate well with the findings of Roepman et al. [3]. However, we do not find an effect of sample storage time on the outcome of our validation analysis as none of these genes are statistically validated by the most recent samples in the validation dataset.

The gene-based validation between the reference and validation studies was hampered by the use of different microarray platforms with different probes and probe content. In order to overcome this problem, a pathway-based supervised analysis was performed, evaluating differences in gene expression between metastasized and non-metastasized HNSCC for predefined tumorigenesis and metastasis related pathways and gene sets. By analyzing groups of functionally related genes, we were able to study the same biological processes in both reference and validation datasets, even though not all genes involved in these processes were present, and the number and nature of the represented genes varied in the respective datasets. In this way, 7 metastasis-related pathways and functionally related gene sets that differentiate between metastasized and non-metastasized HNSCC were statistically validated (Table 4 and Figure 1). These validated pathways are metalloproteinases and regulatory pathways of metalloproteinases, HIF1α induced invasion- and angiogenesis related target genes and the urokinase plasminogen activator system, key pathways involved in invasion, extra cellular matrix remodelling, detachment and angiogenesis, essential steps in the progression to metastatic disease (Tables 4 and 5). Metalloproteinases play a complex role in tumor progression and metastasis. Not only do they facilitate invasion by degrading components of the extracellular matrix, there is also evidence that they are involved in angiogenesis. MMPs that induce metastasis are not only produced by the tumor cells but also by stromal cells and leucocytes, especially along the invasive front of the tumor [36]. The second messenger signalling pathways that lead to expression of MMPs are not fully understood, but there is evidence that MAPK pathways are involved [37]. Three different regulatory MAPK pathways of MMPs have been identified, and in this study two of them show significant differential expression between metastasized and non-metastasized HNSCC: the MAPK1/3 (ERK1/2) and JNK/MAPK pathways. The MAPK1/3 pathway, which is activated by a variety of mitogenic and growth factors, induces FOS and JUN phosphorylation and expression. The JNK/MAPK pathway, which is induced by various inflammatory cytokines, increases transcriptional activity and protein stability of JUN. FOS and JUN are leucine zipper proteins that can dimerize forming the AP-1 transcription factor complexes. JUN, FOS and AP-1 complexes seem to regulate expression of multiple MMPs [37]. The urokinase plasminogen activator system (uPA) mediates invasion and metastasis by catalysing extracellular matrix dissolution, and there is evidence that the uPA system plays a role in cell proliferation, migration and modulation of cell adhesion as well. The potential of components of this system as prognosticators in cancer has been evaluated most extensively in breast cancer, but also in HNSCC [38]. PLAU in particular seems to correlate well with unfavourable outcome, and in this study PLAU correlated well with metastatic HNSCC in both the reference and validation datasets. Hypoxia is a common feature in solid tumors and their metastasis, and can lead to tumor progression in a variety of ways. It induces HIF1α, a transcription factor that regulates angiogenesis as well as cell survival, invasion and metastasis by activating transcription of a host of target genes. The gene sets comprised of HIF1α target genes that are known to be
involved in angiogenesis and invasion are significantly upregulated in metastasized HNSCC in this study [39-41]. As oligonucleotide microarrays measure mRNA levels, results reflect the gene-expression levels in N0 and N+ HNSCC. Post-transcriptional events such as splicing, translation or activation of the proteins encoded by these genes are not measured. Upregulation of genes in a specific pathway as determined by oligonucleotide microarrays therefore may not necessarily mean heightened activity of the pathway. However, it is very plausible that the observed differences in gene-expression levels of genes involved in metastasis-related pathways are responsible for the differences in metastatic potential of N0 and N+ HNSCC.

The aim of this study is not only to identify and validate a gene-expression profile that characterizes metastatic disease in head and neck squamous cell carcinoma, but to provide an analysis strategy that incorporates the available insights in the pathways that lead to metastasis. This supervised pathway-based analysis will not reveal new, previously unknown metastasis related biomarkers. It does however increase our understanding of the biological context of the results. By focusing on pathways and functional gene sets, rather than individual genes, the insight into the biological steps that lead from carcinogenesis to metastatic disease in HNSCC is enhanced. Furthermore, by leaving probes that are not relevant to the biological processes of interest out of the analysis, statistical noise and multiple testing problems associated with microarray analysis are reduced. The most important advantage of this strategy however is the increased comparability of data from different microarray studies. Microarray analyses based on individual genes are highly dependent on the exact gene content of the microarray used in the study, and thus on the chosen microarray platform. In a pathway-based analysis however, gene expression does not have to be measured from every single gene involved in a specific pathway, as long as a representative subset of genes is assessed. These representative subsets of genes involved in a specific pathway may vary between studies. A pathway-based analysis thus can reveal biologically relevant similarity between results of different microarray studies even though the gene contents of the microarray platforms used do not match exactly.

**Conclusion**

In this gene-expression study, we were able to identify and validate several pathways that are differentially expressed between metastasized and non-metastasized HNSCC. These pathways are involved in the processes of extracellular matrix remodeling (MMPs, MMP regulating pathways and the uPA system), hypoxia and angiogenesis (HIF1α regulated angiogenic factors and HIF1α regulated invasion). By focusing on pathways and functional gene sets instead of individual probes in the analysis of microarray data, the biological context of the results is readily interpretable. Furthermore, a supervised, pathway-based analysis reduces multiple testing problems associated with microarray analysis by focusing on a limited number of pathways instead of analyzing all of the probes available on the microarray. Most importantly, the comparability of results from different microarray studies is greatly improved. A supervised, pathway based analysis can reveal biologically relevant similarity between results of different gene-expression studies, even if studies have used different microarray platforms with different probes and probe content.

**Abbreviations**

LLGL2: lethal giant larvae homolog 2; FAP: fibroblast activation protein alpha; PLA2: plasminogen activator urokinase; LAMB1: laminin beta 1; MSC: musculin; COL5A1: collagen type V alpha 1; COL5A3: collagen type V alpha 3; MMP: matrix metalloproteinase; uPA: urokinase plasminogen activator system; HIF1α: hypoxia-inducible factor 1; MAPK: mitogen-activated protein kinase; JNK: c-Jun N-terminal kinase; FOS: v-fos FBJ murine osteosarcoma viral oncogene homolog; JUN: c-Jun oncogene; AP-1: DNA binding/transcription factor AP1.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

EHF participated in the design of the study, in the validation microarray experiments and the statistical analysis, and drafted the manuscript. MJDH carried out the validation microarray experiments and helped with the statistical analysis. JIG participated in the design of the study, carried out part of the statistical analysis and helped to draft the manuscript. JO carried out part of the statistical analysis and helped to draft the manuscript. VTHBMS helped with designing the study and drafting the manuscript. CJC participated in the design of the study, its coordination and drafting of the manuscript. RJBdj conceived of the study, participated in its coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

This research was financially supported by a grant from the Dutch Cancer Society (DCS), Amsterdam, the Netherlands.

**References**

1. Baatenburg de Jong RJ, Hermans J, Molenaar J, Briaire JJ, Le Cassie S: Prediction of survival in patients with head and neck cancer. *Head Neck* 2001, 23(9):718-724.
2. Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J: Lymph node prognostic factors in head and neck squamous cell carcinomas. *Am J Surg* 1994, 168(5):494-498.
3. Roepman P, Wessels LF, Kettelaar N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, Vliet PC van der, Reinders MJ,
Slootweg PJ, Holstege FC: An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005, 37(2):182-186.

4. Jarvinen AK, Hautaniemi S, Edgren H, Alpsten P, Saarela J, Kallioniemi OP, Monni O: Are data from different gene expression microarray platforms comparable? Genomics 2004, 83(6):1164-1168.

5. Tan PK, Downey TJ, Spitznagel EL Jr, Xu P, Fu D, Dimitrov DS, Lempiäki RA, Raaka BM, Carin MC: Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003, 31(19):5676-84.

6. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JC, Geoghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martinez-Murillo F, Morden L, Lee H, Petersen D, Quackenbush J, Scott A, Wilson M, Yang Y, Ye SQ, Yu W: Multiple-laboratory comparison of microarray platforms. Nat Methods 2005, 2(5):345-50.

7. Kuo WP, Jensen TS, Butte AJ, Ohno-Machado L, Kohane IS: Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 2002, 18(3):405-12.

8. Kothapalli R, Yoder SJ, Mane S, Loughran TP Jr: Microarray results: how accurate are they? BMC Bioinformatics 2002, 3:22.

9. Ein-Dor L, Kela I, Getz G, Givol D, Domany E: Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 2005, 21(2):171-8.

10. Roepman P, Kemmeren P, Wessels LF, Slootweg PJ, Holstege FC: Multiple robust signatures for detecting lymph node metastasis in head and neck cancer. Cancer Res 2006, 66(4):2361-65.

11. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M: KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 1999, 27(1):29-34.

12. Kyoto Encyclopedia of Genes and Genomes (KEGG) [http://www.genome.jp/kegg]

13. Biocarta website [http://www.biocarta.com]

14. Manoli Th, Gretz N, Gröne HJ, Kenzelmann M, Eils R, Brors B: Grouping test for pathway analysis improves comparability of data from different microarray datasets. Bioinformatics 2006, 22(20):2500-2506.

15. Nature Genetics website [http://www.nature.com/ng]

16. NCBI Gene Expression Omnibus (GEO) website [http://www.ncbi.nlm.nih.gov/geo]

17. Gentile A, Gentile R, Martinez-Murillo F, Spencer F, A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. J Am Stat Assoc 2004, 99(468):909-917.

18. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F: Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005, 33(20):6175.

19. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, 2005, 7(4):R80.

20. Bioconductor website [http://www.bioconductor.org]

21. Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3(Article 3).

22. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc B 1995, 57:289-300.

23. Stander JH: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3(6):453-458.

24. Goeman JJ, Geer SA van de, de Kort F, van Houwelingen HC: A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004, 20(1):93-99.

25. Yasumura M, Sakakura T, Hidatsa T, Hama T, Sakamoto Y, Yamanaka T, Ohno S, Takai Y: Direct binding of Lgl2 to LGN during mitosis and its requirement for normal cell division. J Biol Chem 2003, 278(8):6761-6765.

26. Mori Y, Kono K, Matsushita M, Chen WT: The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma. Oncology 2004, 67(5–6):411-419.

27. Iwasa S, Okada K, Chen WT, Jin X, Yamane T, Ooi A, Matsusuma M: Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett 2005, 227(2):229-236.

28. Jin X, Iwasa S, Okada K, Matsusuma M, Ooi A: Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm. Anticancer Res 2003, 23(4):3195-3198.

29. Andreassen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72(1):1-22.

30. Duffy MJ, Duggan C: The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004, 37(7):541-548.

31. Fujita M, Khasanov NM, Bosse S, Sekiguchi K, Sasaki T, Carter WG, Ljubimov AV, Black KL, Ljubimova JY: Overexpression of betal-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. Breast Cancer Res Treat 2005, 7(4):R411-421.

32. Patarroyo M, Tryggvason K, Virtanen I: Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 2002, 12(3):197-207.

33. Yu L, Miklouchic J, Sangster N, Perez A, McCormick PJ: MyoR is expressed in nonmyogenic cells and can inhibit their differentiation. Exp Cell Res 2003, 289(1):162-173.

34. Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, Anagnostopoulos I, Lietz A, Sigvardsson M, Jundt F, Juhrens K, Bommer K, Stein H, Dorken B: Intrinsic inhibition of transcription factor E2A by HLH proteins A/BF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006, 7(2):207-215.

35. Schmalbach CE, Chepeha DB, Giordano TJ, Rubin MA, Teknos TN, Bradford CR, Wolf GT, Kuick R, Misek DE, Trask DK, Hanash S: Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130:295-302.

36. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25(1):9-34.

37. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003, 253(1-2):269-285.

38. Duffy MJ, Duggan C: The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004, 37(7):541-548.

39. Hirota K, Semenza GL: Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006, 59(1):15-26.

40. Chou KS, Bue MK, Jeong JW, Moon HE, Kim KW: Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 2003, 36(1):120-127.

41. Vaupe P: The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9(Suppl 5):10-17.

Pre-publication history

The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/8/168/prepub